Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
基于靶向和图像的腺病毒癌症治疗载体
基本信息
- 批准号:8183787
- 负责人:
- 金额:$ 51.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-26 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenovirus VectorAdenovirusesAlabamaAntibodiesBedsBiodistributionBiological Response Modifier TherapyBiometryCapsidCapsid ProteinsCellsChimeric ProteinsClinicalClinical PathologyClinical TrialsColon CarcinomaComplexDimerizationDiseaseDisseminated Malignant NeoplasmDivision of Cancer BiologyDose-LimitingDrug KineticsEngineeringEnvironmentFunctional ImagingGene DeliveryGene TransferGenesGeneticGoalsGrowth FactorHepaticHepatotoxicityHumanImageImmunityImmunoglobulin FragmentsLeucine ZippersLigandsLinkLiverLiver diseasesMalignant NeoplasmsMedicalMetallothioneinMethodsModelingModificationMonitorMusOncogenesOutcomePerformancePhasePhysicsPopulationPositron-Emission TomographyPost-Translational Protein ProcessingPre-Clinical ModelProtein BiosynthesisRadiation OncologyRadiobiologyRadiochemistryRecombinant AntibodyRegional DiseaseReporter GenesResearch InfrastructureResearch PersonnelResourcesSafetySerotypingSiteSpecificityStagingSystemTNFRSF5 geneTechnologyTherapeuticTherapeutic IndexTissuesToxicologyUnited States National Institutes of HealthUniversitiesViralVirionVirusWashingtonWorkbasecellular transductiondesigndesign and constructionflexibilitygene therapyimaging modalityin vivoinnovationmedical schoolsneoplasticnoveloncologyparticlepre-clinicalreceptorresponsesingle photon emission computed tomographytherapeutic targettraffickingtumorvector
项目摘要
DESCRIPTION (provided by applicant): We hypothesize that a novel capsid incorporation approach will allow comprehensive in vivo monitoring of a cancer retargeted vector, and permit the assessment of our novel vector engineering strategy to enable targeted therapy of disseminated neoplastic disease. By investigating adenovirus (Ad) vector design, we anticipate the new information gained from this initiative will demonstrate the utility of our highly novel imaging approach, and validate the specificity of retargeted tumor transduction. The goal of this application is to develop a multi-functional Ad vector that combines both imaging and targeted therapy. To fulfill this goal, we will combine three unique technologies to advance therapeutic targeting of disseminated neoplastic disease: cancer-specific retargeting, liver-detargeting, and non-invasive imaging. We have developed Ad vectors capable of cell-specific targeting, by incorporating targeting single chain antibodies (scFv) into the viral capsid in combination with hexon modification for liver detargeting and evasion of pre-existing immunity. Our innovative Ad targeting approach provides a novel way to circumvent the problem of structural and biosynthetic incompatibility between Ad and complex targeting ligands such as scFv, and could facilitate Ad targeting to a wide variety of clinically important cell populations using novel targeting ligands including recombinant antibodies and growth factors The goal of this application is to develop a multi-functional Ad vector that combines both imaging and targeted therapy. To fulfill this goal, we will combine three unique technologies to advance therapeutic targeting of disseminated neoplastic disease: cancer-specific retargeting, liver-detargeting, and non-invasive imaging. We have developed Ad vectors capable of cell-specific targeting, by incorporating targeting single chain antibodies (scFv) into the viral capsid in combination with hexon modification for liver detargeting and evasion of pre-existing immunity. Our innovative Ad targeting approach provides a novel way to circumvent the problem of structural and biosynthetic incompatibility between Ad and complex targeting ligands such as scFv, and could facilitate Ad targeting to a wide variety of clinically important cell populations Our innovative use of a structural fusion protein incorporating metallothionein into adenovirus pIX gene provides the non-invasive imaging advantages of detecting physical biodistribution and spread of Ad vectors after administration that is not possible employing a reporter gene. Further, the ability to noninvasively observe Ad function on a whole-body level allows the possibility of detecting virus dissemination outside the tumor site(s) for monitoring clinical safety. By combining these modifications in Ad vector design, we anticipate the new information gained from this initiative will demonstrate the utility of our highly novel imaging approach, and validate the specificity of targeted tumor transduction. This work addresses the significant unmet need of new therapies for advanced stage metastatic cancer. The novel design of the proposed imaging approach is distinct from previously described vector imaging modalities, which have been based exclusively on monitoring the expression of reporter genes. In addition, our combined technologies have broad impact on the diverse field of gene therapy, in which the ability to achieve both cell- specific transduction and monitoring is universally required. To accomplish these goals, we have assembled an outstanding team of investigators with expertise in Ad vector design and construction, adenovirus retargeting approaches, preclinical models using Ad vectors, non-invasive PET and SPECT imaging, medical physics, colon cancer oncology and clinical trials, clinical pathology, biostatistics, and preclinical toxicology.
PUBLIC HEALTH RELEVANCE: The goal of this application is to develop a multi-functional adenovirus vector that combines both imaging and targeted therapy. We will provide a combination of modifications that are optimal for cell-specific adenovirus targeting in metastatic colon cancer gene therapy and for monitoring adenovirus biodistribution by non- invasive SPECT and PET imaging.
描述(由申请人提供):我们假设一种新的衣壳结合方法将允许对癌症重靶向载体进行全面的体内监测,并允许评估我们的新型载体工程策略,以实现播散性肿瘤疾病的靶向治疗。通过对腺病毒(Ad)载体设计的研究,我们预计从这项研究中获得的新信息将证明我们高度新颖的成像方法的实用性,并验证重靶向肿瘤转导的特异性。本应用程序的目标是开发一种多功能的广告载体,结合成像和靶向治疗。为了实现这一目标,我们将结合三种独特的技术来推进播散性肿瘤疾病的治疗靶向:癌症特异性重靶向、肝脏去靶向和非侵入性成像。我们已经开发了能够细胞特异性靶向的Ad载体,通过将靶向单链抗体(scFv)结合六邻体修饰结合到病毒衣壳中,以使肝脏脱靶和逃避预先存在的免疫。我们创新的Ad靶向方法提供了一种新的方法,可以避免Ad与复杂靶向配体(如scFv)之间的结构和生物合成不相容问题,并且可以使用新的靶向配体(包括重组抗体和生长因子)促进Ad靶向各种临床重要细胞群。本应用的目标是开发一种多功能Ad载体,结合成像和靶向治疗。为了实现这一目标,我们将结合三种独特的技术来推进播散性肿瘤疾病的治疗靶向:癌症特异性重靶向、肝脏去靶向和非侵入性成像。我们已经开发了能够细胞特异性靶向的Ad载体,通过将靶向单链抗体(scFv)结合六邻体修饰结合到病毒衣壳中,以使肝脏脱靶和逃避预先存在的免疫。我们创新的Ad靶向方法提供了一种新的方法来规避Ad与复杂靶向配体(如scFv)之间的结构和生物合成不相容问题。我们创新地将金属硫蛋白结构融合蛋白结合到腺病毒pIX基因中,提供了检测Ad载体在给药后的物理生物分布和传播的非侵入性成像优势,这是使用报告基因无法实现的。此外,在全身水平上无创观察Ad功能的能力允许检测肿瘤部位外的病毒传播,从而监测临床安全性。通过在Ad载体设计中结合这些修改,我们预计从这一倡议中获得的新信息将证明我们高度新颖的成像方法的实用性,并验证靶向肿瘤转导的特异性。这项工作解决了晚期转移性癌症新疗法的重大未满足需求。所提出的成像方法的新设计不同于先前描述的矢量成像模式,后者完全基于监测报告基因的表达。此外,我们的联合技术对基因治疗的不同领域有着广泛的影响,在这些领域中,实现细胞特异性转导和监测的能力是普遍需要的。为了实现这些目标,我们组建了一支优秀的研究团队,他们在Ad载体的设计和构建、腺病毒重靶向方法、使用Ad载体的临床前模型、非侵入性PET和SPECT成像、医学物理学、结肠癌肿瘤学和临床试验、临床病理学、生物统计学和临床前毒理学方面具有专业知识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Terry Curiel其他文献
David Terry Curiel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Terry Curiel', 18)}}的其他基金
A Novel Vector Platform to Actualize T Cell Modification In Vivo
一种在体内实现 T 细胞修饰的新型载体平台
- 批准号:
10663022 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
Endothelial-targeted adenovirus for organ-selective gene editing in vivo
用于体内器官选择性基因编辑的内皮靶向腺病毒
- 批准号:
10228031 - 财政年份:2019
- 资助金额:
$ 51.79万 - 项目类别:
Endothelial-targeted adenovirus for organ-selective gene editing in vivo
用于体内器官选择性基因编辑的内皮靶向腺病毒
- 批准号:
9810634 - 财政年份:2019
- 资助金额:
$ 51.79万 - 项目类别:
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION
心房传导 3D 体外疾病模型
- 批准号:
10166441 - 财政年份:2017
- 资助金额:
$ 51.79万 - 项目类别:
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION
心房传导 3D 体外疾病模型
- 批准号:
10228624 - 财政年份:2017
- 资助金额:
$ 51.79万 - 项目类别:
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 51.79万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 51.79万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Young Scientists (B)